[Therapeutic approach to EBV infection].
Morio
Tomohiro
T
Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School.
D023181:Antimicrobial Cationic Peptides; D000998:Antiviral Agents / Q000145:classification; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives; D001562:Benzimidazoles; D015195:Drug Design; D020031:Epstein-Barr Virus Infections / Q000628:therapy* / Q000821:virology; D004854:Herpesvirus 4, Human; D006801:Humans; D006918:Hydroxyurea; D007167:Immunotherapy; D011804:Quinolines; D034741:RNA, Small Interfering; D012263:Ribonucleosides; D004004:Dichlororibofuranosylbenzimidazole / Q000031:analogs & derivatives
D023181:Antimicrobial Cationic Peptides; D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; D001562:Benzimidazoles; D006918:Hydroxyurea; D011804:Quinolines; D034741:RNA, Small Interfering; D012263:Ribonucleosides; C455641:PNU183792; C039202:neuramide; C034935:clevudine; C400401:maribavir; D004004:Dichlororibofuranosylbenzimidazole